Keywords:
Allakos (NASDAQ: ALLK) today released data from ENIGMA 2, a 24-week randomized, double-blind, placebo-controlled phase 3 study of lirentelimab in patients with biopsy-confirmed eosinophilic gastritis (EG) and / or ...
CAMEROON MAGAZINE - GM22/12/20211 Mins read56 ViewsKeywords:
Le cours de l’action Allakos Inc (NASDAQ : ALLK) – une société...
ByCAMEROON MAGAZINE - GM22/12/2021Allakos (ALLK) announces data from ENIGMA 2, a 24-week phase 3 study...
ByCAMEROON MAGAZINE - GM22/12/2021